Actively Recruiting
Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Led by Jiangsu vcare pharmaceutical technology co., LTD · Updated on 2026-01-02
420
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
CONDITIONS
Official Title
Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The subject understands and voluntarily signs the informed consent form and is willing and able to comply with the study protocol
- The subject is between 18 and 70 years of age (including borderline values) at the time of signing the informed consent form, regardless of gender
- The subject has been diagnosed with ankylosing spondylitis according to the 1984 New York Revised Criteria
You will not qualify if you...
- Allergy to VC005, similar drugs, or their excipients
- Prior organ transplantation with ongoing need for immunosuppressant use
- Any condition that the investigator considers makes the subject unsuitable for participation in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
X
xiaojuan lai
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here